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LETTERS TO THE EDITOR
Adjuvant Use of
Epidermal Growth
Factor Receptor Kinase
Inhibitors May Prevent
Bone Metastases
in Patients with
Non-small Cell Lung
Carcinoma
To the Editor:
Epidermal growth factor receptors
(EGFRs) are frequently overexpressed in
non-small cell carcinoma of the lung.1
Activation of EGFR cytoplasmic receptor
tyrosine kinases regulate essential cellular
functions including proliferation, survival,
migration, and differentiation and play a
central role in the progression of solid
tumors.2 The prominent role of EGFR
signaling in many tumor types has
prompted the development of pharmaco-
logical inhibitors such as gefitinib and er-
lotinib, which disrupt EGFR kinase activ-
ity by binding the ATP site within the
catalytic kinase domain. Parathyroid hor-
mone-related protein (PTHrP) is a gene
product regulated by EGFR that influ-
ences the pathogenesis of lung squamous
cell carcinomas. One study demonstrated
that autocrine stimulation of the EGFR
pathway is a major activator of PTHrP
gene expression in keratinocytes, and
disruption of the EGFR in keratino-
cytes with the EGFR-tyrosine kinase
inhibitor PD153035 reduced PTHrP
mRNA up to 80%.3 Furthermore, a
recent study reported that administra-
tion of gefitinib reduced hypercalcae-
mia and decreased PTHrP production
in hypercalcaemic mice with HARA
and RWGT2 xenografts.4
Bone metastasis is very common
among patients with late-stage breast,
prostate, and lung cancer. When patients
die from the disease, a significant pro-
portion of tumor burden is in the bone,5
which is often accompanied by debili-
tating complications such as bone frac-
ture, severe bone pain, nerve compres-
sion, and hypercalcemia. Tumor-derived
factor PTHrP stimulates osteoblasts to
secrete receptor activator of NF-B li-
gand (RANKL). Binding of RANKL to
its receptor activator of NF-B on oste-
oclast precursor cells results in activa-
tion of gene program for osteoclast dif-
ferentiation and maturation, ending with
increased bone resorption. Bone resorp-
tion by osteoclasts releases a number of
growth factors embedded in the bone
matrix, including IGFs, TGF-, PDGF,
and BMP. These growth factors can
stimulate the growth of cancer cells and
enhance the production of bone metas-
tasis factors, such as PTHrP, CTGF,
IL-11, and VEGF, thus forming the so-
called “vicious cycle” in bone metasta-
sis.6 Given this information, we propose
that, through the inhibition of PTHrP in
non-small cell carcinoma cells, EGFR
tyrosine kinase inhibitors may decrease
the risk of bone metastases in patients
with operable non-small cell carcinoma.
This proposal warrants further investi-
gation in clinical trials.
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To the Editor:
The epidermal growth factor re-
ceptor (EGFR) tyrosine kinase inhibi-
tors (TKIs) gefitinib and erlotinib are
effective in a subset of non-small cell
lung cancers (NSCLCs). Skin-related
toxicities are the main side effects of
EGFR TKI use in clinical practice.1,2
The most common skin manifestation is
a rash described as a follicular or papu-
lar pustular eruption.1,2
Patients treated with gefitinib and
erlotinib can also exhibit hair abnormal-
ities.1 The most commonly described
alterations include curlier, finer, and
more brittle hair on the scalp and ex-
tremities.2 Trichomegaly, or curling of
eyelashes and eyebrows, and hypertri-
chosis of the face can also be seen.1
Significant or severe alopecia has sel-
dom been reported in patients receiving
TKI monotherapy.1,2 The best described
hair loss pattern among patients with
NCLC treated with TKI is frontal “an-
drogen-like” scalp alopecia, which can
be seen many months after initiation of
therapy.2
We describe a patient with meta-
static NSCLC who developed severe al-
opecia while receiving erlotinib mono-
therapy at the recommended dose of 150
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